Koselugo Approved in EU for Plexiform Neurofibromas
AstraZeneca's Koselugo (selumetinib) has been approved in the European Union for the treatment of symptomatic, inoperable plexiform neurofibromas in adult patients with neurofibromatosis type 1.
The approval is based on results from the KOMET trial, a placebo-controlled global Phase III trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting and published in The Lancet.
The European Commission's approval follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP).
Koselugo is an oral, selective MEK inhibitor, developed by Alexion, AstraZeneca Rare Disease.
Author's summary: Koselugo approved in EU for neurofibromatosis type 1 treatment.More News
- Microsoft Azure global service outage impacts Minecraft and Xbox services worldwide
- Fashion lovers step out for Carol Byrne X Very Partywear Edit
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- The Tech Symphony: AI's Crescendo and the Gadget Orchestra
- Mineola, Quitman bands advance - Wood County Monitor
- JESUS & BARABBAS: Pius X and the False Pentecost of Politics
- How to watch Texas high school football: Malakoff vs. Mount Vernon, Oct. 31
- Malakoff romps past Emory Rains with big first half
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- Ahsoka Season 2 Gets Exciting Update From Rosario Dawson